MET-097

Clinical trials are becoming increasingly complex and expensive as they target smaller patient populations and face stricter regulations, driving the need for smarter and more efficient trial designs.

Metsera is seeking a $289 million IPO to fund the Phase III trial of its lead candidate, MET-097i, an injectable GLP-1 receptor agonist for obesity.

MBX Biosciences announced positive topline results from its Phase 1 trial of MBX 1416 in healthy volunteers, indicating a favorable safety profile.

Metsera's MET-097i, an ultra-long acting GLP-1 receptor agonist, showed substantial placebo-adjusted weight loss of up to 11.3% after 12 weeks in a Phase 2a trial.

Merus' petosemtamab demonstrates a 36% overall response rate in recurrent/metastatic head and neck squamous cell carcinoma, with median overall survival of 11.4 months.